Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Urinary Tract Infection

  Free Subscription

Articles published in Int J Antimicrob Agents

Retrieve available abstracts of 56 articles:
HTML format

Single Articles

    July 2021
  1. ZHANG H, Liang B, Wang J, Cai Y, et al
    Non-carbapenem beta-lactam/beta-lactamase inhibitors versus carbapenems for urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review.
    Int J Antimicrob Agents. 2021 Jul 30:106410.
    PubMed     Abstract available

    May 2021
  2. DELORY T, Gravier S, Pluart DL, Gaube G, et al
    Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study.
    Int J Antimicrob Agents. 2021 May 14:106361.
    PubMed     Abstract available

    August 2020
  3. SEO H, Lee SC, Chung H, Ra SH, et al
    Clinical and Microbiologic Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia.
    Int J Antimicrob Agents. 2020 Aug 2:106126.
    PubMed     Abstract available

    July 2020
  4. MOWLABOCCUS S, Daley D, Pang S, Gottlieb T, et al
    Identification and Characterisation of Fosfomycin Resistance in Escherichia coli Urinary Tract Infection Isolates from Australia.
    Int J Antimicrob Agents. 2020 Jul 30:106121.
    PubMed     Abstract available

  5. NGUYEN HM, Graber CJ
    A Critical Review of Cephalexin and Cefadroxil for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection in the Era of "Bad Bugs, Few Drugs".
    Int J Antimicrob Agents. 2020 Jul 10:106085.
    PubMed     Abstract available

    June 2020
  6. PARSONSON F, Legg A, Halford M, McCarthy K, et al
    Contemporaneous management of ampicillin infusions in the outpatient setting through the use of therapeutic drug monitoring.
    Int J Antimicrob Agents. 2020;55:105975.
    PubMed     Abstract available

    May 2020
  7. WANG T, Wu G, Wang J, Cui Y, et al
    Comparison of Single-dose Fosfomycin Tromethamine and Other Antibiotics for Lower Uncomplicated Urinary Tract Infection in Women and Asymptomatic Bacteriuria in Pregnant Women:a systematic review and meta-analysis.
    Int J Antimicrob Agents. 2020 May 14:106018.
    PubMed     Abstract available

    April 2020
  8. NABOKA YL, Mavzyiutov AR, Kogan MI, Gudima IA, et al
    Does Escherichia coli have pathogenic potential at low level bacteriuria in recurrent, uncomplicated urinary tract infections?
    Int J Antimicrob Agents. 2020 Apr 21:105983.
    PubMed     Abstract available

  9. CAI T, Palagin I, Brunelli R, Cipelli R, et al
    Office-based approach to urinary tract infections on 50000 patients: results from the REWIND study.
    Int J Antimicrob Agents. 2020 Apr 20:105966.
    PubMed     Abstract available

    March 2020
  10. GARCIA-FERNANDEZ S, Garcia-Castillo M, Melo-Cristino J, Pinto MF, et al
    In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study.
    Int J Antimicrob Agents. 2020;55:105887.
    PubMed     Abstract available

  11. MARAOLO AE, Mazzitelli M, Trecarichi EM, Buonomo AR, et al
    Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
    Int J Antimicrob Agents. 2020;55:105891.
    PubMed     Abstract available

    January 2020
  12. TUMBARELLO M, Raffaelli F, Peghin M, Losito AR, et al
    Characterisation and risk-factor profiling of P. aeruginosa urinary tract infections: pinpointing those likely to be caused by multidrug-resistant strains.
    Int J Antimicrob Agents. 2020 Jan 10:105900.
    PubMed     Abstract available

  13. DA SILVA BNM, Faria AR, de Souza SDSR, Colodette SS, et al
    Expression of VanA-type vancomycin resistance in a clinical isolate of Enterococcus faecium showing insertion of IS19 in the vanS gene.
    Int J Antimicrob Agents. 2020 Jan 10:105897.
    PubMed     Abstract available

    November 2019
  14. CHENG IL, Chen YH, Lai CC, Tang HJ, et al
    The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and urinary tract infections-A meta-analysis of randomized controlled trials.
    Int J Antimicrob Agents. 2019 Nov 28. pii: S0924-8579(19)30329.
    PubMed     Abstract available

  15. ZYKOV IN, Frimodt-Moller N, Smabrekke L, Sundsfjord A, et al
    The efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model.
    Int J Antimicrob Agents. 2019 Nov 23. pii: S0924-8579(19)30322.
    PubMed     Abstract available

  16. ROY SM, Riley MA
    Evaluation of the potential of colicins to prevent extraluminal contamination of urinary catheters by Escherichia coli.
    Int J Antimicrob Agents. 2019;54:619-625.
    PubMed     Abstract available

    September 2019
  17. BARRAUD O, Ravry C, Francois B, Daix T, et al
    Shotgun metagenomics for microbiome and resistome detection in septic patients with urinary tract infections.
    Int J Antimicrob Agents. 2019 Sep 16. pii: S0924-8579(19)30252.
    PubMed     Abstract available

    August 2019
  18. XU Q, Jiang J, Zhu Z, Xu T, et al
    Efflux pumps AcrAB and OqxAB contribute to nitrofurantoin resistance in an uropathogenic Klebsiella pneumoniae isolate.
    Int J Antimicrob Agents. 2019;54:223-227.
    PubMed     Abstract available

    July 2019
  19. KARLOWSKY JA, Lagace-Wiens PRS, Adam HJ, Baxter MR, et al
    In vitro susceptibility of urinary Escherichia coli isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007-2016.
    Int J Antimicrob Agents. 2019;54:62-68.
    PubMed     Abstract available

    June 2019
  20. MALMROS K, Huttner BD, McNulty C, Rodriguez-Bano J, et al
    Comparison of antibiotic treatment guidelines for urinary tract infections in 15 European countries - results of an online survey.
    Int J Antimicrob Agents. 2019 Jun 20. pii: S0924-8579(19)30168.
    PubMed     Abstract available

  21. KONGNAKORN T, Wagenlehner F, Falcone M, Tichy E, et al
    Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections.
    Int J Antimicrob Agents. 2019 Jun 13. pii: S0924-8579(19)30161.
    PubMed     Abstract available

    May 2019
  22. GARCIA-FERNANDEZ S, Garcia-Castillo M, Bou G, Calvo J, et al
    Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study.
    Int J Antimicrob Agents. 2019;53:682-688.
    PubMed     Abstract available

  23. PARVEZ S, Misba L, Ahmad QT, Khan AU, et al
    Emergence of Extremely Drug-Resistant and Uropathogenic New Delhi Metallo-beta-Lactamse-6 (blaNDM-6)-producing Citrobacter werkmanii.
    Int J Antimicrob Agents. 2019;53:703-704.

    April 2019
  24. BASSETTI M, Castaldo N, Cattelan A, Mussini C, et al
    Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
    Int J Antimicrob Agents. 2019;53:408-415.
    PubMed     Abstract available

    March 2019
  25. GOLDSTEIN E, MacFadden DR, Karaca Z, Steiner CA, et al
    Antimicrobial resistance prevalence, rates of hospitalization with septicemia and rates of mortality with sepsis in adults in different US states.
    Int J Antimicrob Agents. 2019 Mar 6. pii: S0924-8579(19)30056.
    PubMed     Abstract available

    February 2019
  26. QUEK WM, Teng CB, Tan YZ, Chong K, et al
    Outcomes of Fosfomycin Use in Ceftriaxone-Resistant Enterobacteriaceae Urinary Tract Infection in the Elderly.
    Int J Antimicrob Agents. 2019;53:195-196.

    October 2018
  27. ZHONG H, Zhao XY, Zhang ZL, Gu ZC, et al
    Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis.
    Int J Antimicrob Agents. 2018;52:443-450.
    PubMed     Abstract available

    September 2018
  28. MCKINNON J, Roy Chowdhury P, Djordjevic SP
    Genomic analysis of multidrug-resistant Escherichia coli ST58 causing urosepsis.
    Int J Antimicrob Agents. 2018;52:430-435.
    PubMed     Abstract available

    August 2018
  29. LISHMAN H, Costelloe C, Hopkins S, Johnson AP, et al
    Exploring the relationship between primary care antibiotic prescribing for urinary tract infections, Escherichia coli bacteraemia incidence and antibiotic resistance: an ecological study.
    Int J Antimicrob Agents. 2018 Aug 23. pii: S0924-8579(18)30239.
    PubMed     Abstract available

  30. CHUANG L, Ratnayake L
    Overcoming challenges of treating extensively drug-resistant Acinetobacter baumannii bacteraemic urinary tract infection.
    Int J Antimicrob Agents. 2018 Aug 3. pii: S0924-8579(18)30207.

    July 2018
  31. BOUXOM H, Fournier D, Bouiller K, Hocquet D, et al
    Which non-carbapenem antibiotics are active against extended-spectrum beta-lactamase-producing Enterobacteriaceae?
    Int J Antimicrob Agents. 2018;52:100-103.
    PubMed     Abstract available

  32. GIUFRE M, Errico G, Accogli M, Monaco M, et al
    Emergence of NDM-5-producing Escherichia coli sequence type 167 clone in Italy.
    Int J Antimicrob Agents. 2018;52:76-81.
    PubMed     Abstract available

    June 2018
  33. DEMONCHY E, Courjon J, Ughetto E, Durand M, et al
    Cefoxitin-based antibiotic therapy for extended-spectrum beta-lactamase-producing Enterobacteriaceae prostatitis: a prospective pilot study.
    Int J Antimicrob Agents. 2018;51:836-841.
    PubMed     Abstract available

    April 2018
  34. MENDES RE, Castanheira M, Woosley LN, Stone GG, et al
    Molecular beta-lactamase characterization of gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and
    Int J Antimicrob Agents. 2018 Apr 11. pii: S0924-8579(18)30103.
    PubMed     Abstract available

    March 2018
  35. XIAO AJ, Huntington JA, Long J, Caro L, et al
    Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.
    Int J Antimicrob Agents. 2018 Mar 26. pii: S0924-8579(18)30075.
    PubMed     Abstract available

  36. BOUSQUET A, Bugier S, Larreche S, Bigaillon C, et al
    Clinical isolates of Escherichia coli solely resistant to mecillinam: prevalence and epidemiology.
    Int J Antimicrob Agents. 2018;51:493-497.
    PubMed     Abstract available

    February 2018
  37. SEIFERT H, Korber-Irrgang B, Kresken M
    In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
    Int J Antimicrob Agents. 2018;51:227-234.
    PubMed     Abstract available

    January 2018
  38. GARCIA-CASTILLO M, Garcia-Fernandez S, Gomez-Gil R, Pitart C, et al
    Activity of ceftazidime-avibactam against carbapenemase-producing enterobacteriaceae from urine samples obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain.
    Int J Antimicrob Agents. 2018 Jan 22. pii: S0924-8579(18)30014.
    PubMed     Abstract available

    October 2017
  39. SOBKE A, Makarewicz O, Baier M, Bar C, et al
    Empiric treatment of lower urinary tract infections in the face of spreading multi-drug resistance: in vitro study of nitroxoline effectiveness.
    Int J Antimicrob Agents. 2017 Oct 27. pii: S0924-8579(17)30374.
    PubMed     Abstract available

    September 2017
  40. KIM SA, Altshuler J, Paris D, Fedorenko M, et al
    Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum beta-lactamase producing enterobacteriaceae.
    Int J Antimicrob Agents. 2017 Sep 21. pii: S0924-8579(17)30353.
    PubMed     Abstract available

    June 2017
  41. CHIEN JY, Yu CJ, Hsueh PR
    High incidence of fluoroquinolone resistance and effect of efflux pump inhibitors on moxifloxacin resistance among Mycobacterium tuberculosis isolates causing urinary tract infection in Taiwan.
    Int J Antimicrob Agents. 2017 Jun 28. pii: S0924-8579(17)30207.
    PubMed     Abstract available

  42. SHAH KJ, Cherabuddi K, Shultz J, Borgert S, et al
    Ampicillin for the treatment of complicated urinary tract infections caused by vancomycin resistant enterococcus spp (VRE): a single-center university hospital experience.
    Int J Antimicrob Agents. 2017 Jun 27. pii: S0924-8579(17)30218.
    PubMed     Abstract available

  43. MEZZATESTA ML, La Rosa G, Maugeri G, Zingali T, et al
    In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens.
    Int J Antimicrob Agents. 2017;49:763-766.
    PubMed     Abstract available

    May 2017
  44. BOURDELLON L, Thilly N, Fougnot S, Pulcini C, et al
    Impact of selective reporting of antibiotic susceptibility test results on the appropriateness of antibiotics chosen by french general practitioners in urinary tract infections: a randomised controlled case-vignette study.
    Int J Antimicrob Agents. 2017 May 31. pii: S0924-8579(17)30173.
    PubMed     Abstract available

  45. BOIX-PALOP L, Xercavins M, Badia C, Obradors M, et al
    Emerging extended-spectrum beta-lactamase-producing Klebsiella pneumoniae causing community-onset urinary tract infections: a case-control-control study.
    Int J Antimicrob Agents. 2017 May 24. pii: S0924-8579(17)30170.
    PubMed     Abstract available

    April 2017
  46. BI W, Li B, Song J, Hong Y, et al
    Antimicrobial susceptibility and mechanisms of fosfomycin resistance in extended-spectrum beta-lactamase-producing Escherichia coli strains from urinary tract infections in Wenzhou, China.
    Int J Antimicrob Agents. 2017 Apr 26. pii: S0924-8579(17)30135.
    PubMed     Abstract available

    November 2016
  47. GUET-REVILLET H, Tomini E, Emirian A, Join-Lambert O, et al
    Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study.
    Int J Antimicrob Agents. 2016 Nov 15. pii: S0924-8579(16)30334.
    PubMed     Abstract available

    July 2016
  48. GRAU S, Luque S, Echeverria-Esnal D, Sorli L, et al
    Urinary micafungin levels are sufficient to treat urinary tract infections caused by Candida spp.
    Int J Antimicrob Agents. 2016 Jul 5. pii: S0924-8579(16)30148.
    PubMed     Abstract available

  49. WANG LH, Liu PP, Wei DD, Liu Y, et al
    Clinical isolates of uropathogenic Escherichia coli ST131 producing NDM-7 metallo-beta-lactamase in China.
    Int J Antimicrob Agents. 2016;48:41-5.
    PubMed     Abstract available

    June 2016
  50. VAN DER MEE-MARQUET N, Diene SM, Chopin F, Goudeau A, et al
    Enigmatic occurrence of NDM-7 enzyme in the community.
    Int J Antimicrob Agents. 2016;47:505-7.

    May 2016
  51. VEVE MP, Wagner JL, Kenney RM, Grunwald JL, et al
    Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum beta-lactamase urinary tract infections.
    Int J Antimicrob Agents. 2016 May 12. pii: S0924-8579(16)30092.
    PubMed     Abstract available

    April 2016
  52. ZMARLICKA MT, Cardwell SM, Crandon JL, Nicolau DP, et al
    Evaluation of a disease state management guideline for urinary tract infection.
    Int J Antimicrob Agents. 2016 Apr 22. pii: S0924-8579(16)30051.
    PubMed     Abstract available

  53. LOB SH, Hoban DJ, Sahm DF, Badal RE, et al
    Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii.
    Int J Antimicrob Agents. 2016;47:317-23.
    PubMed     Abstract available

    February 2016
  54. JEAN SS, Coombs G, Ling T, Balaji V, et al
    Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010-2013.
    Int J Antimicrob Agents. 2016 Feb 17. pii: S0924-8579(16)00042.
    PubMed     Abstract available

    July 2015
  55. ROGER C, Nucci B, Molinari N, Bastide S, et al
    Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations.
    Int J Antimicrob Agents. 2015;46:21-7.
    PubMed     Abstract available

    April 2015
  56. ROGERS BA, Ingram PR, Runnegar N, Pitman MC, et al
    Sequence type 131 fimH30 and fimH41 subclones amongst Escherichia coli isolates in Australia and New Zealand.
    Int J Antimicrob Agents. 2015;45:351-8.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Urinary Tract Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.